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Abstract  We  report  a  case  of  a  63-year-old-man  presenting  with  chronic  diarrhea  and  weight
loss while  on  olmesartan  treatment  for  hypertension.  Investigation  showed  multiple  nutritional
deﬁciencies  associated  with  diffuse  intestinal  villous  atrophy.  Serologies  for  celiac  disease
were negative  and  other  causes  of  villous  atrophy  were  excluded.  Olmesartan  as  a  precipitant
agent was  suspected  and  withdrawn.  Clinical  improvement  occurred  in  days  with  no  need  for
other therapeutic  measures.  Follow-up  at  three  months  showed  clinical  remission  and  almost
complete recovery  of  intestinal  atrophy.
Olmesartan  is  an  angiotensin  receptor  blocker  commonly  prescribed  for  the  management  of
hypertension.  Spruelike  enteropathy  associated  with  this  drug  is  a  recently  described  entity
with few  cases  reported.  It  presents  with  chronic  diarrhea  and  intestinal  villous  atrophy  and
should be  included  in  its  differential  diagnosis.  This  case  intends  to  alert  clinicians  for  the
possibility  of  this  event  in  a  patient  on  treatment  with  this  drug.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALAVRAS-CHAVE
Atroﬁa;
Doenc¸as
Enteropatia  Induzida  pelo  Olmesartan:  Uma  Causa  Incomum  de  Atroﬁa  Vilositária
Resumo  Apresentamos  o  caso  de  um  homem  de  63  anos  com  diarreia  crónica  e  perda  pon-Gastrointestinais; deral. Apresentava  hipertensão  arterial  tratada  com  olmesartan.  A  investigac¸ão  complementar
utricionais  associados  a  atroﬁa  vilositária  intestinal  difusa.  As  serolo-
m  negativas  e  outras  causas  de  atroﬁa  vilositária  foram  excluídas.
 como  agente  precipitante,  sendo  este  suspenso.  Observou-se  mel-
necessidade  de  outras  medidas  terapêuticas.  No  seguimento,  aos  3Antanosistas  dos
Recetores  da
Angiotensina
II/efeitos  adversos
mostrou múltiplos  déﬁces  n
gias de  doenc¸a  celíaca  fora
Suspeitou-se  do  olmesartan
horia clínica  em  dias,  sem  
meses, constatou-se  remissão  clínica  e  recuperac¸ão  quase  completa  da  atroﬁa  intestinal.
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O  olmesartan  é  um  bloqueador  dos  recetores  da  angiotensina,  geralmente  prescrito  no  trata-
mento da  hipertensão.  A  enteropatia  ‘‘spruelike’’  associada  a  este  fármaco  é  uma  entidade
recentemente  descrita,  com  poucos  casos  reportados.  Manifesta-se  por  diarreia  crónica  asso-
ciada a  atroﬁa  vilositária  intestinal,  devendo  ser  incluída  no  seu  diagnóstico  diferencial.  Com
este caso  pretende-se  alertar  os  clínicos  para  a  possibilidade  deste  evento  em  doentes  sob
tratamento  com  este  fármaco.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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the  terminal  ileum  could  not  be  intubated.  Colonic  random
biopsies  excluded  microscopic  colitis  or  other  abnormali-
ties.  Upper  endoscopy  evidenced  a  discrete  attenuation  of
duodenal  villous  pattern  without  other  ﬁndings  (Fig.  1).. Introduction
he  most  common  cause  of  villous  atrophy  is  celiac
isease.1,2 The  villous  atrophy  results  from  injury  to  the
mall  intestine  and  leads  to  loss  of  absorptive  surface  area,
eduction  of  digestive  enzymes,  and  consequential  impaired
bsorption  of  micronutrients.3 Negative  celiac  serology  or
onresponse  to  a  gluten-free  diet  implies  a  broad  and
hallenging  differential  diagnosis  which  includes  Crohn’s  dis-
ase,  enteric  infections  (e.g.  Giardia  lamblia),  collagenous
prue,  tropical  sprue,  common  variable  immunodeﬁciency,
utoimmune  enteropathy,  hematological  malignancies  and
edication-associated  enteropathy.2 Regarding  the  latter,
lmesartan  medoxomil,  an  angiotensin  receptor  blocker  for
he  management  of  hypertension,  has  been  recently  recog-
ized  as  a  cause  of  ‘‘sprue-like  enteropathy’’.4--6
We  report  a  case  of  severe  enteropathy  associated  with
lmesartan  use.
. Clinical case
 63-year-old  man  was  admitted  to  our  department  com-
laining  of  progressive  diarrhea  and  signiﬁcant  weight  loss
12  kg)  for  one  year.  He  reported  between  5  and  7  daily
pisodes  of  bulky,  watery  and  nonbloody  diarrhea.  Over  the
receding  two  weeks,  it  was  associated  with  severe  fatigue,
norexia  and  vomiting.  He  denied  abdominal  pain,  fever  or
ther  symptoms.  There  was  no  history  of  recent  travels  or
ick  contacts.
Apart  from  arterial  hypertension,  treated  with  olmesar-
an  and  hydrochlorothiazide  (20/12.5  mg)  for  two  years,  his
ast  medical  history  was  unremarkable.
The  patient  had  already  undergone  total  colonoscopy
nd  abdominal  computed  tomography  with  no  remarkable
ndings.  A  gluten  and  lactose-free  diet  were  tried  without
mprovement.  He  also  failed  initial  conservative  treatment
ith  a  trial  of  oral  antibiotic  for  possible  small  bowel  bac-
erial  overgrowth.
On  presentation  at  our  department,  his  body  mass  index
as  20  kg/m2 (normal  (N):  18.5--24.99  kg/m2),  close  to  the
ower  limit  of  normal.  Muscle  wasting  was  also  seen  without
vident  weakness.  There  was  no  peripheral  edema  or  other
elevant  ﬁndings  on  physical  examination.
Laboratory  evaluation  revealed:  hemoglobin  11.6  g/dL
normal:  13--17)  with  normal  mean  corpuscular  volume  and
ean  corpuscular  hemoglobin;  serum  potassium  1.8  mmol/L
N:  3.6--5.1),  phosphorus  1.7  mg/dL  (N:  2.3--4.7),  magne-
ium  1.3  mg/dL  (N:  3.6--5.1),  corrected  calcium  8.6  mg/dL
F
aN:  8.8--10);  albumin  2.9  g/dL  (N:  3.4--4.8),  total  protein
.9  g/dL  (N:  6.2--8.5),  aspartate  aminotransferase  205  UI/L
N:  5--34),  alanine  aminotransferase  106  UI/L  (N  <  55)  and
rotein  C-reaction  25  mg/L  (N:  <5  mg/L).  The  prothrombine
ime  (PT)  was  increased  (26.6  s;  N:  9.4--13)  as  well  as  acti-
ated  partial  thromboplastin  time  (aPTT)  (50  s;  N:  20--40).
Other  laboratory  work-up  was  unremarkable  including
eucogram,  serum  glucose,  B12  vitamin,  folic  acid,  trans-
lutaminase  antibodies,  serum  immunoglobulins,  thyroid
timulating  hormone  and  serology  for  human  immunodeﬁ-
iency  virus.  Platelets,  bleeding  time  and  ﬁbrinogen  were
lso  normal.
Other  causes  for  hypertransaminasemia  were  addition-
lly  excluded  (no  alcohol  consumption;  bilirubin,  alkaline
hosphatase,  gamma-glutamyl  transpeptidase,  serum  iron,
erritin,  transferrin  saturation,  cholesterol  and  triglycerides
ere  normal;  hepatitis  B  and  C  serologies  were  negative;
ntinuclear  antibodies  and  smooth  muscle  antibodies  were
egative  and  abdominal  ultrasound  excluded  liver  or  biliary
bnormalities).
Stool  examination  namely  cultures,  Clostridium  difﬁcile
oxin  assay,  ova  and  parasites  was  unrevealing.
A  colonoscopy  was  repeated  and,  despite  all  efforts,igure  1  Initial  upper  endoscopy  showing  a  discrete  attenu-
tion of  villous  pattern  of  the  second  portion  of  the  duodenum.
Olmesartan-induced  enteropathy  
Figure  2  Small  intestinal  biopsy  showing  villous  atrophy  and
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vchronic  lymphocytic  inﬁltration  of  the  lamina  propria  (hema-
toxylin  and  eosin,  4×).
Histopathological  examination  conﬁrmed  a  partial  villous
atrophy  and  chronic  lymphocytic  inﬁltration  of  the  lam-
ina  propria  (Fig.  2).  Capsule  endoscopy  was  performed  and
demonstrated  a  diffuse  ﬂattening  of  the  small  bowel  villi
(Fig.  3).
We  suspected  of  olmesartan-associated  sprue-like
enteropathy.  This  drug  was  therefore  withdrawn  along  with
replacement  of  electrolytes  and  vitamin  K  administration.
Prompt  improvement  was  achieved  within  a  few  days.  One
week  after  hospital  admission,  the  patient  was  discharged
without  diarrhea  or  need  for  nutritional/electrolyte  support
and  began  to  gain  weight.  Olmesartan  was  switched  to
amlodipine.Three  months  later,  a  complete  recovery  of  weight
(12.5  kg)  was  seen  along  with  full  normalization  of  lab-
oratory  tests  (hemoglobin,  electrolytes,  albumin,  TP,
aPTT,  protein-C  reaction  and  aminotransferases).  Upper
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Figure  3  Capsule  endoscopy  showing  mark93
ndoscopy  and  capsule  endoscopy  (Fig.  4) were,  again,
erformed  and  showed  normal  small  bowel  appearance.
istopathological  analysis  of  duodenal  biopsies  conﬁrmed
n  almost  complete  recovery  of  duodenal  villi  and  no  lym-
hocyte  inﬁltration  (Fig.  5).  At  sixth  month  follow-up,  the
atient  remained  asymptomatic  with  no  laboratory  abnor-
alities.
.  Discussion
e  described  a case  of  a  patient  presenting  with  chronic
iarrhea  and  malabsorption  as  evidenced  by  multiple  nutri-
ional  deﬁcits  including  electrolyte  imbalance  and  reduced
erum  albumin.  Prolonged  PT  and  aPTT  in  a  patient  not
aking  vitamin  K  antagonists,  with  no  evidence  of  liver
isease,  biliary  obstruction  or  disseminated  intravascular
oagulation  suggested,  in  this  clinical  setting,  vitamin  K
alabsorption.  In  addition,  villous  atrophy  was  present
hroughout  the  entire  small  bowel  as  demonstrated  by  cap-
ule  endoscopy,  which  explains  the  malabsoption.
In  our  case,  celiac  disease,  the  most  common  cause  of
illous  atrophy,1,2 was  excluded  by  serology  methods  and
he  lack  of  clinical  response  to  a  gluten-free  diet.  After
xcluding  other  causes  of  villous  atrophy,  we  considered  an
lmesartan-associated  enteropathy.
Olmesartan  medoxomil  is  an  angiotensin  II  receptor
locker  approved  for  the  treatment  of  hypertension  since
002.7 A  sprue-like  enteropathy  associated  with  olmesar-
an  was  ﬁrst  reported  by  Rubio-Tapia  et  al.4 and  since  then,
imilar  cases  have  been  described,  although  mainly  as  case
eports  or  small  case  series.6,8--15 As  a  result,  United  States
ood  and  Drug  Administration  reported  this  olmesartan  asso-
iated  adverse  event  via  a MedWatch  alert  in  July  2013.
Clinical  presentation  of  this  entity  include  chronic  diar-
hea,  vomiting,  abdominal  pain,  bloating,  weight  loss  and
atigue.4,6,11 More  severe  cases  with  dehydration,4,9,13 acute
enal  failure9 and  a  case  of  colonic  perforation11 have  been
eported.  According  to  previous  descriptions,  the  duration
f  exposure  to  olmesartan  before  the  onset  of  diarrhea  has
aried  between  several  months  and  years.4,6 In  our  case,  it
ook  one  year  to  present  symptoms,  which  is  in  accordance
ith  the  timing  reported.
Laboratory  investigation  may  show  normocytic,  nor-
ochromic  anemia,  hypoalbuminemia  and  one  or  multiple
ed  villous  atrophy  of  the  small  bowel.
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Figure  4  Follow-up  capsule  endoscopy  sho
electrolyte  abnormalities,4 as  evidenced  in  our  case.  Human
leukocyte  antigen  (HLA)  assessment,  when  performed,  may
reveal  a  higher  prevalence  of  DQ2  or  DQ8  haplotypes  than
expected  for  the  general  population,  which  suggests  a  pos-
sible  role  for  genetics  in  this  enteropathy.4,6
Upper  endoscopy  may  be  normal,  show  a  nodular  appear-
ance  of  the  duodenal  mucosa  or  ﬂattening  of  villi.6 In  our
case,  only  a  discrete  attenuation  of  duodenal  villous  pat-
tern  was  observed.  Capsule  endoscopy,  however,  highlighted
a  diffuse  and  obvious  ﬂattening  of  the  small  bowel  villi.
The  most  common  histopathological  ﬁnding  is  intestinal
villous  atrophy  (either  total  or  partial),  which  may  be  asso-
ciated  with  variable  degrees  of  mucosal  inﬂammation.  In
contrast  to  celiac  disease,  ﬂattening  of  villi  is  not  always
associated  with  increased  intra-epithelial  lymphocytes  and
Figure  5  Histopathological  image  showing  almost  complete
recovery  of  duodenal  villi  three  months  after  discontinuing
olmesartan  (hematoxylin  and  eosin,  4×).
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twing  normal  small  bowel  appearance.
nﬂammation.6 In  addition,  involvement  of  the  stomach  and
olon  with  lymphocytic  aggregation  was  also  reported  by
ome  authors,4,8,15 suggesting  that  this  disorder  may  affect
he  entire  gastrointestinal  tract.
Regarding  treatment,  previous  reports  have  demon-
trated  clinical  remission  in  all  patients  after  discontinu-
tion  of  olmesartan.4,6,8--13,15 Moreover,  almost  all  patients
ave  shown  histological  recovery  of  the  duodenum  after
rug  withdrawal  (although  follow-up  intestinal  biopsies  have
ot  been  done  systematically  in  all  patients).4,6,10,12 In  con-
rast  to  other  enteropathies,  such  as  celiac  disease  that
ay  take  years  to  achieve  histological  recovery,  despite
dequate  treatment,16,17 olmesartan-induced  enteropathy
s  associated  with  a  quick  mucosal  recovery  (median  eight
onths  from  the  suspension  of  the  drug  to  follow-up
iopsies).4
In  our  case,  the  complete  resolution  of  symptoms  and
alabsorption,  the  intestinal  villous  atrophy  improvement
ithout  any  other  therapeutic/dietary  measures  besides  dis-
ontinuation  of  the  drug  and  the  absence  of  other  causes  of
nteropathy  support  this  diagnosis.  Deliberate  rechallenge
est  with  olmesartan  was  not  performed  because  of  the  life-
hreatening  nature  of  the  disease  and  was  not  clinically
ertinent.
One  additional  interesting  ﬁnding,  in  our  case,  was  the
ypertransaminasemia  that  normalized  after  the  discon-
inuation  of  the  drug.  After  excluding  other  causes  for
his  ﬁnding,  we  believe  that  this  could  be  linked  to  the
nteropathy,  similar  to  that  described  for  celiac  disease.
eliac  patients  with  hypertransaminasemia  have  an  impor-
ant  increase  in  intestinal  permeability  compared  with  those
hose  liver  enzymes  are  normal.18 One  proposed  explana-
ion  for  hepatic  involvement  in  these  patients  is  that  the
ncreased  intestinal  permeability  may  ease  the  entry  of
oxins,  antigens,  and  inﬂammatory  substances  (cytokines
nd/or  autoantibodies)  to  the  portal  circulation  that,  sub-
equently,  play  a  role  in  liver  injury.19 In  our  case  of  severe
lmesartan-induced  enteropathy  we  speculate  that  similar
echanisms  could  be  on  the  basis  of  hypertransaminasemia.
he  report  of  more  cases  of  this  drug-induced  enteropathy
s  crucial  to  clarify  these  ﬁndings.
The  pathogenesis  of  this  entity  is  still  unclear.  The  long
nterval  between  the  beginning  of  olmesartan  therapy  and
he  onset  of  diarrhea  suggests  a  cell-mediated  immune
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mechanism.4,11 Some  reports  have  indicated  a  potential
inhibitory  effect  of  angiotensin  receptor  blockers  on  trans-
forming  growth  factor,  which  is  responsible  for  gut  immune
homeostasis.20,21 Another  proposed  theory  is  related  to
a  pro-apoptotic  effect  of  angiotensin  (AT)  II  on  intesti-
nal  epithelial  cells.  Angiotensin  II  binds  to  two  receptor
forms,  AT1  and  AT2,  with  different  properties  and  differ-
ent  gastrointestinal  distribution.  AT1  receptor  is  expressed
throughout  the  whole  alimentary  tract,  while  AT2  receptor  is
expressed  particularly  in  the  duodenum  and  jejunum.22 Sun
et  al.  suggested  that  angiotensin  II  through  binding  to  AT2
receptor  up-regulates  pro-apoptotic  proteins,  such  as  Bax
and  GATA-6,  in  association  with  a  down-regulation  of  Bcl-2,
an  anti-apoptotic  protein.23 Olmesartan  shows  high  afﬁnity
for  AT1  receptors.  In  case  of  saturation  of  this  receptors,
circulating  angiotensin  II  could  bind  to  AT2  receptor  result-
ing  in  a  pro-apoptotic  effect  and,  consequently,  to  villous
atrophy.6 Further  investigations  are  needed  to  elucidate  the
physiopathological  mechanisms  underlying  this  entity.
Another  issue  to  clarify  is  if  other  angiotensin  II
receptor  blockers  can  have  a  similar  adverse  reaction.
Recently,  valsartan  was  implicated  in  a  case  of  ‘‘sprue-
like’’  enteropathy.24 Nevertheless,  cases  of  enteropathy
related  to  other  angiotensin  II  receptor  inhibitors  seem  to  be
much  less  frequent  than  olmesartan-induced  enteropathy.5
The  selective  role  of  olmesartan  might  be  explained  by  its
conversion  into  the  active  form  in  the  intestine,  its  longer
half-life  and  higher  efﬁcacy  compared  to  other  sartans.25
In  conclusion,  this  report  intends  to  alert  the  clinical
community  for  this  probably  underreported  problem,11 since
this  condition  is  serious  and  olmesartan  is  commonly  pre-
scribed  for  the  treatment  of  hypertension.  Negative  serology
for  celiac  disease  and  absence  of  response  to  a  gluten-free
diet  on  patients  taking  olmesartan  should  aware  clinicians
for  the  possibility  of  this  condition.  We  show  iconogra-
phy  namely  capsule  endoscopic  images,  that  document  the
endoscopic  ﬁndings  associated  with  this  entity  and  can
add  information  on  the  hallmarks  of  this  entity.  Increasing
reports  of  this  drug-induced  enteropathy  may  lead  to  the
identiﬁcation  of  more  cases,  a  better  characterization  of
this  entity  and  an  earlier  diagnosis,  with  obvious  beneﬁts  to
patients.
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